Phase 2 Oesophageal Cancer Trial, Recruiting NCT06531434 Sponsor: National Cheng-Kung University Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06531434
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer), confirmed by laboratory testing of tissue samples
  • People whose cancer has grown into nearby organs (known as T4 stage disease)
  • People aged between 18 and 70 years old
  • People who are reasonably active and able to carry out daily activities without significant limitation, based on a standard health scoring system (a score of 0 or 1 on the ECOG scale)
  • People whose blood test results fall within acceptable ranges, including healthy levels of red blood cells, white blood cells, platelets, liver function, and kidney function (confirm with trial site for exact values)

Who may not be able to join:

  • People who have previously received chemotherapy treatment
  • People who have had a heart attack within the last three months
  • People with a history of unstable chest pain (unstable angina), lung inflammation (interstitial pneumonia), scarring of the lungs (fibrotic lung disease), or severe emphysema
  • People who currently have another type of cancer
  • People who have an infection that is not under control
  • People who are pregnant or currently breastfeeding
  • People whose oesophagus had a hole or tear (perforation) at the time of their diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +886-6-2353535

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
National Cheng-Kung University Hospital
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
30 April 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Overall response rate of the treatment; Duration of response (DOR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov